Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Nov;57(10):1384-92.
doi: 10.1093/cid/cit549. Epub 2013 Sep 6.

Vitamin D3 supplementation and upper respiratory tract infections in a randomized, controlled trial

Judy R Rees  1 , Kristy Hendricks, Elizabeth L Barry, Janet L Peacock, Leila A Mott, Robert S Sandler, Robert S Bresalier, Michael Goodman, Roberd M Bostick, John A Baron
Affiliations
Randomized Controlled Trial

Vitamin D3 supplementation and upper respiratory tract infections in a randomized, controlled trial

Judy R Rees et al. Clin Infect Dis. 2013 Nov.

Abstract

Background: Randomized controlled trials testing the association between vitamin D status and upper respiratory tract infection (URTI) have given mixed results. During a multicenter, randomized controlled trial of colorectal adenoma chemoprevention, we tested whether 1000 IU/day vitamin D(3) supplementation reduced winter episodes and duration of URTI and its composite syndromes, influenza-like illness (ILI; fever and ≥2 of sore throat, cough, muscle ache, or headache) and colds (no fever, and ≥2 of runny nose, nasal congestion, sneezing, sore throat, cough, swollen or tender neck glands).

Methods: The 2259 trial participants were aged 45-75, in good health, had a history of colorectal adenoma, and had a serum 25-hydroxyvitamin D level ≥12 ng/mL. They were randomized to vitamin D(3) (1000 IU/day), calcium (1200 mg/day), both, or placebo. Of these, 759 participants completed daily symptom diaries. Secondary data included semiannual surveys of all participants.

Results: Among those who completed symptom diaries, supplementation did not significantly reduce winter episodes of URTI (rate ratio [RR], 0.93; 95% confidence interval [CI], .79-1.09) including colds (RR, 0.93; 95% CI, .78-1.10) or ILI (RR, 0.95; 95% CI, .62-1.46), nor did it reduce winter days of illness (RR, 1.13; 95% CI, .90-1.43). There was no significant benefit according to adherence, influenza vaccination, body mass index, or baseline vitamin D status. Semiannual surveys of all participants (N = 2228) identified no benefit of supplementation on ILI (odds ratio [OR], 1.14; 95% CI, .84-1.54) or colds (OR, 1.03; 95% CI, .87-1.23).

Conclusions: Supplementation with 1000 IU/day vitamin D(3) did not significantly reduce the incidence or duration of URTI in adults with a baseline serum 25-hydroxyvitamin D level ≥12 ng/mL.

Trial registration: ClinicalTrials.gov NCT00153816.

Keywords: randomized controlled trial; upper respiratory tract infection; vitamin D.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
CONSORT (Consolidated Standards of Reporting Trials) flow diagram. Abbreviation: 25(OH)D, 25-hydroxyvitamin D.
See this image and copyright information in PMC

References

    1. Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral respiratory tract infection in the United States. Arch Intern Med. 2003;163:487–94. - PubMed
    1. Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007;25:5086–96. - PubMed
    1. Smiley D. Seasonal factors in the incidence of the acute respiratory infections. Am J Hygiene. 1926;6:621–6.
    1. Cannell JJ, Vieth R, Umhau JC, et al. Epidemic influenza and vitamin D. Epidemiol Infect. 2006;134:1129–40. - PMC - PubMed
    1. Hope-Simpson RE. The role of season in the epidemiology of influenza. J Hyg (Lond) 1981;86:35–47. - PMC - PubMed

Publication types

Associated data